Breaking News Instant updates and real-time market news.

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

, PFE

Pfizer

$36.45

-0.01 (-0.03%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16

Oncolytics, PrECOG announce collaboration for Bracelet-1 study in metastatic BC

Oncolytics Biotech (ONCY) and PrECOG LLC, a cancer research network, announced their collaboration in which PrECOG will run the BRACELET-1 study. The principal investigator will be Kathy Miller, MD, Ballve-Lantero Professor of Oncology at Indiana University School of Medicine and Associate Director of Clinical Research at Indiana University Melvin and Bren Simon Cancer Center, and PrECOG member. The study will take place in 15 centers in the United States and will evaluate the ability of pelareorep to make tumors immunologically visible to checkpoint inhibitors. The BRACELET-1 study seeks to replicate a previous trial that supported an advantage in overall survival through the use of pelareorep in patients with hormone receptor-positive metastatic breast cancer. It is being designed as a phase 2, three-arm, 48-patient open-label study for second-line treatment in these patients. The first arm will be paclitaxel alone, the second arm will be paclitaxel plus pelareorep, and the third arm will be paclitaxel plus pelareorep, plus the PD-L1 checkpoint inhibitor, avelumab.The design is expected to be finalized in the coming weeks with input from Oncolytics' co-development partners Pfizer (PFE) and Merck KGaA (MKGAY). It will then go to the FDA for review. The study is anticipated to begin enrollment in Q1 2020.

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

PFE

Pfizer

$36.45

-0.01 (-0.03%)

MKGAY

Merck KGaA

$0.00

(0.00%)

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Dec

ONCY Oncolytics
$0.47

-0.0138 (-2.83%)

09/04/19
ROTH
09/04/19
INITIATION
Target $6.8
ROTH
Buy
Oncolytics initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson started coverage of Oncolytics with a Buy rating and $6.80 price target given its "promising" oncolytic virus for multiple tumors. At this time, based on announced clinical plans, the analyst considers the company's lead product candidate pelareorep to have potential value in breast cancer, pancreatic cancer, and multiple myeloma, and sees potential for it to be approved in all of these indications in 2024.
09/04/19
09/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ASE Technology (ASX) initiated with a Buy at Goldman Sachs. 2. XPEL (XPEL) initiated with a Buy at Craig-Hallum. 3. Papa John's (PZZA) initiated with a Buy at Northcoast while Domino's Pizza (DPZ) was initiated with a Neutral. 4. Oncolytics (ONCY) initiated with a Buy at Roth Capital. 5. WWE (WWE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$36.45

-0.01 (-0.03%)

10/17/19
BOFA
10/17/19
INITIATION
Target $37
BOFA
Neutral
Pfizer reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Pfizer with a Neutral rating and $37 price target. The analyst believes valuation reflects the near-term pipeline and the need for visibility on the pipeline to offset future LOEs.
10/16/19
BOFA
10/16/19
INITIATION
Target $37
BOFA
Neutral
Pfizer reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Pfizer with a Neutral rating and $37 price target, saying that he believes the company's near-term pipeline is priced into shares and that he needs additional clarity on the pipeline.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
MKGAY Merck KGaA
$0.00

(0.00%)

10/04/19
LOOP
10/04/19
NO CHANGE
Target $51
LOOP
Buy
Entegris price target raised to $51 from $47 at Loop Capital
Loop Capital analyst Chris Kapsch raised his price target on Entegris (ENTG) to $51 and kept his Buy rating. The analyst says the stock continues to perform well in spite of the "sanguine" macro backdrop and continued weakness in the semiconductor capital equipment spending trends thanks to the company's "resilient" consumables-biased portfolio and improving visibility regarding the industry's "node transitions at the leading edges". Kapsch adds that following the takeout of Entegris' rival Versum (VSM) by Merck KgA (MKGAY), its valuation may be accounting for an M&A premium.
06/28/19
BOFA
06/28/19
DOWNGRADE
BOFA
Underperform
Merck KGaA downgraded to Underperform from Neutral at BofA/Merrill
04/16/19
04/16/19
DOWNGRADE
Target $53

Hold
Versum Materials downgraded to Hold from Buy at Loop Capital
As previously reported, Loop Capital analyst Chris Kapsch downgraded Versum Materials (VSM) to Hold and lowered his price target to $53 from $56, saying the bidding process for the company has "run its course" after its board agreed to Merck KGaA's (MKGAY) "sweetened" deal over that of Entegris' (ENTG) merger of equals proposal. The analyst says the stock has limited upside from its current levels and expects the deal to close in the second half of 2019.
04/08/19
STFL
04/08/19
DOWNGRADE
Target $53
STFL
Hold
Versum Materials downgraded to Hold from Buy at Stifel
Stifel analyst Patrick Ho downgraded Versum Materials (VSM) to Hold from Buy after the company received a revised all-cash offer of $53 per share offer from Merck KGaA (MKGAY) and Entegris (ENTG) announced in a press release that it would not counter this bid. With Entegris turning down a potential counter and walking away, Ho said he does not believe there will be any additional counter, hostile, or unsolicited bidding. He raised his price target for Versum shares to $53 from $46.

TODAY'S FREE FLY STORIES

CDLX

Cardlytics

$39.85

0.17 (0.43%)

16:44
11/12/19
11/12
16:44
11/12/19
16:44
Earnings
Cardlytics raises FY19 revenue view to $196M-$200M from $180M-$190M 

Consensus $190.49M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

RNG

RingCentral

$172.89

2.57 (1.51%)

, AVYA

Avaya

$12.53

0.08 (0.64%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Hot Stocks
RingCentral issues 2.17M Class A shares to Avaya »

RingCentral, Inc. (RNG)…

RNG

RingCentral

$172.89

2.57 (1.51%)

AVYA

Avaya

$12.53

0.08 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 09

    Dec

SSTI

ShotSpotter

$20.35

-0.01 (-0.05%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
ShotSpotter guides initial FY20 revenue $48M-$50M, consensus $55.94M »

Management also expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Hot Stocks
SmileDirectClub targets long-term marketing, selling expenses 40%-45% of sales »

SmileDirectClub said in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SSTI

ShotSpotter

$20.35

-0.01 (-0.05%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
ShotSpotter cuts FY19 revenue view to $40M-$40.5M from $42M-$44.5M 

Consensus $42.9M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CDLX

Cardlytics

$39.85

0.17 (0.43%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
Breaking Earnings news story on Cardlytics »

Cardlytics sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

SSTI

ShotSpotter

$20.35

-0.01 (-0.05%)

16:42
11/12/19
11/12
16:42
11/12/19
16:42
Earnings
ShotSpotter reports Q3 EPS 4c, consensus 3c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CDLX

Cardlytics

$39.85

0.17 (0.43%)

16:42
11/12/19
11/12
16:42
11/12/19
16:42
Earnings
Cardlytics reports Q3 EPS 3c, consensus (15c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

FIXX

Homology Medicines

$11.47

0.1 (0.88%)

16:42
11/12/19
11/12
16:42
11/12/19
16:42
Earnings
Homology Medicines reports Q3 EPS (67c), consensus (50c) »

Reports Q3 revenue $441K,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BREW

Craft Brew

$16.22

8.89 (121.28%)

16:42
11/12/19
11/12
16:42
11/12/19
16:42
Earnings
Craft Brew Alliance backs FY19 CapEx view $13M-$17M »

Backs FY19 depletions and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PXD

Pioneer Natural

$136.18

2.48 (1.85%)

16:41
11/12/19
11/12
16:41
11/12/19
16:41
Initiation
Pioneer Natural initiated  »

Pioneer Natural initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:41
11/12/19
11/12
16:41
11/12/19
16:41
Hot Stocks
SmileDirectClub says legal expenses doubled in Q3, will continue into Q4 »

SmileDirectClub said in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

EOG

EOG Resources

$73.29

-0.47 (-0.64%)

16:41
11/12/19
11/12
16:41
11/12/19
16:41
Initiation
EOG Resources initiated  »

EOG Resources initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BREW

Craft Brew

$16.22

8.89 (121.28%)

16:41
11/12/19
11/12
16:41
11/12/19
16:41
Earnings
Craft Brew Alliance reports Q3 EPS (6c), consensus 7c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BCEL

Atreca

$11.52

-0.14 (-1.20%)

16:41
11/12/19
11/12
16:41
11/12/19
16:41
Earnings
Atreca reports Q3 EPS (57c), consensus (72c) »

As of September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:40
11/12/19
11/12
16:40
11/12/19
16:40
Earnings
SmileDirectClub sees Q4 revenue $196M-$201M, consensus $207.57M »

Sees Q4 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DAL

Delta Air Lines

$57.23

(0.00%)

, UAL

United Airlines

$92.74

-0.76 (-0.81%)

16:40
11/12/19
11/12
16:40
11/12/19
16:40
Recommendations
Delta Air Lines, United Airlines, American Airlines, Southwest, Alaska Air, JetBlue analyst commentary  »

UBS rolls out…

DAL

Delta Air Lines

$57.23

(0.00%)

UAL

United Airlines

$92.74

-0.76 (-0.81%)

AAL

American Airlines

$29.52

-1.07 (-3.50%)

LUV

Southwest

$57.87

-0.4 (-0.69%)

ALK

Alaska Air

$70.87

-1.015 (-1.41%)

JBLU

JetBlue

$19.31

-0.44 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 12

    Dec

  • 23

    Jan

ABM

ABM

$38.31

0.67 (1.78%)

16:40
11/12/19
11/12
16:40
11/12/19
16:40
Hot Stocks
ABM appointd Josh Feinberg as EVP Chief Strategy and Transformation Officer »

ABM announced that Josh…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBII

Marrone Bio

$1.29

0.01 (0.78%)

16:40
11/12/19
11/12
16:40
11/12/19
16:40
Earnings
Marrone Bio reports reports Q3 EPS (14c), consensus (5c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CPRX

Catalyst Pharmaceuticals

$4.91

-0.1 (-2.00%)

16:39
11/12/19
11/12
16:39
11/12/19
16:39
Earnings
Catalyst Pharmaceuticals reports Q3 EPS 13c, consensus 11c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CDAY

Ceridian

$55.11

1.16 (2.15%)

16:39
11/12/19
11/12
16:39
11/12/19
16:39
Syndicate
Ceridian holders to sell 10M shares of common stock »

Affiliates of Thomas H.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PRTK

Paratek Pharmaceuticals

$4.05

0.02 (0.50%)

16:39
11/12/19
11/12
16:39
11/12/19
16:39
Earnings
Paratek sees FY19 NUZYRA U.S. net product sales likely at lower end of guidance »

The company now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ALGT

Allegiant Travel

$168.28

-1.69 (-0.99%)

16:38
11/12/19
11/12
16:38
11/12/19
16:38
Hot Stocks
Allegiant Travel reports October scheduled service traffic up 2.2% »

Reports October scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTK

Paratek Pharmaceuticals

$4.05

0.02 (0.50%)

16:38
11/12/19
11/12
16:38
11/12/19
16:38
Earnings
Paratek reports Q3 EPS ($1.00), consensus ($1.05) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ABEO

Abeona Therapeutics

$2.28

-0.21 (-8.43%)

16:37
11/12/19
11/12
16:37
11/12/19
16:37
Earnings
Abeona Therapeutics reports Q3 EPS (35c), consensus (44c) »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.